Psychedelics Co. Numinus Narrows Loss In Q3, Reports QoQ Decrease In Revenue, Gross Profit
Psychedelics Co. Numinus Narrows Loss In Q3, Reports QoQ Decrease In Revenue, Gross Profit
On June 20, 2024, the company announced that it had executed a letter of intent to acquire Psychedelics-focused mental health care company Numinus Wellness Inc. (TSX:NUMI) (OTCQX:NUMIF), announced its third quarter financial results on Thursday for the three months ended May 31, 2024.
以致力於精神療法所需的致幻劑爲重點的保健公司 Numinus Wellness Inc. (TSX:NUMI) (OTCQX:NUMIF) 宣佈於2024年5月31日結束的三個月內的第三季度財務業績報告。這家公司週四公佈了其第三季度的財務業績報告。
"In the third quarter of 2024, we continued to make progress on our program to transition Numinus to an operationally lean company prepared to benefit from the anticipated growth in psychedelic therapy. Key to the program is achieving profitability with our existing operations and leveraging our significant experience and expertise to opportunities in the broad market," Payton Nyquvest, Numinus founder and CEO said.
“2024年第三季度，我們繼續推進過渡使Numinus成爲一家運營精益的公司，並準備從迷幻療法預期的增長中受益。項目的關鍵是通過我們現有的業務實現盈利，並利用我們在廣泛市場中的重要經驗和專門知識的機遇，” Numinus創始人兼CEO Payton Nyquvest表示。
Q3 2024 Financial Highlights
2024年Q3財務亮點：
- Revenue totaled CA$4.3 million ($3.15 million), representing a sequential decrease of 1.9%.
- Numinus Wellness clinics' revenue amounted to CA$3.36 million, representing a 7% decrease compared to CA$3.6 million during the prior quarter, and a drop of 18% compared to CA$4.1 million in the prior year's period.
- Revenues from Cedar Clinical Research were CA0.8 million, representing an increase of 11% compared to the second quarter of 2024, and a 20% decrease compared to the third quarter of 2023.
- Revenues from Practitioner Training increased by 114% from CA$78,837 during the previous quarter to CA$168,830.
- Gross profit totaled CA$1 million, representing a 9.8% decline quarter-over-quarter.
- Gross margin declined 200 basis points in the third quarter of 2024 to 22% from 24% in the prior period.
- Operating expenditures and other items were CA$6.1 million, compared to CA$7.3 million in the previous quarter.
- Cash position of CA$3.7 million as of May 31, 2024.
- Loss and comprehensive loss was CA$5.1 million, representing a sequential drop from CA$5.7 million.
- 營業收入總額爲430萬加元（315萬美元），環比下降1.9%。
- Numinus Wellness 診所的營業收入共計336萬加元，相比上一季度的360萬加元減少了7%，相比上一年同期的410萬加元下降了18%。
- Cedar Clinical Research 的營業收入爲80萬加元，環比增長11%，相比 2023 年第三季度減少20%。
- 從實踐家培訓中獲得的收入從上一季度的78,837加元增加到168,830加元，增長114%。
- 毛利潤總計100萬加元，環比下降9.8%。
- 毛利率在2024年第三季度下降了200個點子，從上一期的24%下降到22%。
- 運營支出及其他費用爲610萬加元，而上一季度爲730萬加元。
- 現金持有總額截至2024年5月31日爲370萬加元。
- 虧損及綜合虧損爲510萬加元，環比下降了60萬加元。
Read Also: Psychedelics-Focused Numinus Plans To Leverage This AI Technology Via New Strategic Acquisition
讀更多：致力於精神療法的 Numinus 打算通過新的戰略收購利用這種人工智能技術。
Other Business Highlights
其他業務亮點
- Transitioned out of Canadian clinical operations through an agreement with the Canadian Centre for Psychedelic Healing (Field Trip Health).
- Enrolment in Numinus training programs increased to over 1,650 learners, compared to over 1,400 in the second quarter of 2024, with learners joining from 18 countries.
- Managed 15 clinical trials at Cedar Clinical Research.
- Provided 15,750 client appointments in U.S. Numinus Wellness Clinics; this represents a 3.2% increase from the prior year.
- 與加拿大致幻療法中心（Field Trip Health）達成協議，退出了加拿大的臨床運營。
- Numinus 培訓計劃的註冊人數增加到 1650 名學習者，而第二季度的註冊人數爲 1400 名，其中來自 18 個國家的學習者加入其中。
- 在 Cedar Clinical Research 管理了 15 項臨床試驗。
- 在美國的 Numinus Wellness 診所中提供了 15,750 次客戶預約，較去年同期增長了 3.2%。
On June 20, 2024, the company announced that it had executed a letter of intent to acquire MedBright AI Investments (CSE:MBAI) by way of a statutory plan of arrangement.
2024年6月20日，該公司宣佈已簽署意向書，通過法定整合計劃方式收購 MedBright AI 投資公司 (CSE:MBAI)。
The strategic combination of MedBright's AI machine-learning platform with Numinus' significant expertise in traditional therapy, clinic management, patient care, insurance reimbursement and psychedelic-assisted treatment is expected to enhance revenue generation through a unique AI-enabled offering available to the growing number of U.S. mental health providers.
將MedBright的人工智能機器學習平台與Numinus在傳統療法、診所管理、患者護理、保險報銷和輔助迷幻療法的重要專業知識相結合，預計通過一種獨特的AI啓用提供給美國不斷增長的心理健康服務提供商來增強營業收入。
"Our proposed acquisition of MedBright AI further amplifies our opportunities by leveraging our experience and expertise in clinical care and insurance reimbursement into a licensed offering available to mental health clinics, therapists and practitioners across the U.S.," Nyquvest said.
“我們擬收購MedBright AI進一步擴大機會，通過將我們在臨床護理和保險報銷方面的經驗和專業知識運用到一項已獲許可的診所服務中，提供給美國的心理健康診所、治療師和從業者，” Nyquvest說。
NUMIF Price Action
NUMIF價格走勢
Numinus' shares traded 3.12% higher at $0.033 per share at the time of writing on Friday,
截至週五寫作時，Numinus的股價每股0.033美元，漲幅爲3.12%。
- Numinus Wellness Q2 2024 Revenue Declines Amid Clinic Reshuffling And Expected Industry Trends
- Numinus Wellness2024年第二季度營業收入因門診調整和預期行業趨勢而下降。
